Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.28% | -10.18% | -12.57% | -19.99% | -16.16% |
| Total Depreciation and Amortization | -6.42% | -4.70% | -1.66% | 6.43% | 11.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.40% | -24.57% | -32.23% | 63.83% | 81.68% |
| Change in Net Operating Assets | 68.19% | 55.45% | 62.97% | 35.57% | 11.06% |
| Cash from Operations | 11.88% | 14.54% | 18.50% | 11.38% | 3.46% |
| Capital Expenditure | 84.15% | 87.49% | 81.57% | 81.78% | 65.05% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.79% | 145.82% | 222.37% | 294.93% | 90.29% |
| Cash from Investing | 52.79% | 164.47% | 217.44% | 277.83% | 120.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 53.21% | -- | -99.77% | -99.87% | -99.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | 75.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 31.82% | -559.74% | -- | 59.60% | 89.15% |
| Cash from Financing | 90.07% | 88.24% | -100.42% | -100.52% | -100.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 132.98% | 93.53% | 112.61% | 109.97% | -460.13% |